Syntegon acquires Telstar
Innovative technologies and comprehensive services to strengthen Syntegon’s strategic growth
Innovative technologies and comprehensive services to strengthen Syntegon’s strategic growth
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
This strategic decision will unlock significant value for our scientific and industrial products business
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Subscribe To Our Newsletter & Stay Updated